AU2017248665B2 - Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin - Google Patents

Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin Download PDF

Info

Publication number
AU2017248665B2
AU2017248665B2 AU2017248665A AU2017248665A AU2017248665B2 AU 2017248665 B2 AU2017248665 B2 AU 2017248665B2 AU 2017248665 A AU2017248665 A AU 2017248665A AU 2017248665 A AU2017248665 A AU 2017248665A AU 2017248665 B2 AU2017248665 B2 AU 2017248665B2
Authority
AU
Australia
Prior art keywords
hypertension
subject
rtx
administration
resiniferatoxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017248665A
Other languages
English (en)
Other versions
AU2017248665A1 (en
Inventor
Hanjun Wang
Irving H. ZUCKER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Nebraska System
Original Assignee
University of Nebraska–Lincoln
University of Nebraska System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Nebraska–Lincoln, University of Nebraska System filed Critical University of Nebraska–Lincoln
Publication of AU2017248665A1 publication Critical patent/AU2017248665A1/en
Application granted granted Critical
Publication of AU2017248665B2 publication Critical patent/AU2017248665B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2017248665A 2016-04-13 2017-04-13 Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin Active AU2017248665B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662322079P 2016-04-13 2016-04-13
US62/322,079 2016-04-13
PCT/US2017/027480 WO2017180907A1 (en) 2016-04-13 2017-04-13 Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin

Publications (2)

Publication Number Publication Date
AU2017248665A1 AU2017248665A1 (en) 2018-11-08
AU2017248665B2 true AU2017248665B2 (en) 2023-01-05

Family

ID=60039929

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017248665A Active AU2017248665B2 (en) 2016-04-13 2017-04-13 Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin

Country Status (8)

Country Link
US (3) US20170296506A1 (enExample)
EP (1) EP3442523A4 (enExample)
JP (3) JP6980694B2 (enExample)
KR (2) KR102395342B1 (enExample)
CN (2) CN120114438A (enExample)
AU (1) AU2017248665B2 (enExample)
IL (2) IL262328B2 (enExample)
WO (1) WO2017180907A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113490745A (zh) 2018-12-21 2021-10-08 索伦托药业有限公司 神经周施用树脂毒素治疗适应不良性疼痛
WO2020154261A1 (en) 2019-01-22 2020-07-30 Sorrento Therapeutics, Inc. Method for treating osteoarthritis pain by administering resiniferatoxin
CN116744867A (zh) * 2020-08-11 2023-09-12 索伦托药业有限公司 通过神经消融治疗肺部炎性疾病
WO2022245791A1 (en) * 2021-05-18 2022-11-24 Sorrento Therapeutics, Inc. Presurgical perineural administration of resiniferatoxin for reduction of post-operative pain

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101522181A (zh) * 2006-10-04 2009-09-02 纽若科伊公司 诱导低体温药物在治疗局部缺血的应用
US20150080460A1 (en) * 2013-09-18 2015-03-19 Board Of Regents Of The University Of Nebraska Methods for Administration and Methods for Treating Cardiovascular Diseases with Resiniferatoxin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211230D0 (en) * 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
CA2607219A1 (en) * 2005-05-18 2007-02-15 Neuraxon, Inc. Substituted benzimidazole compounds with dual nos inhibitory activity and mu opioid agonist activity
SI1976521T1 (sl) * 2006-01-25 2015-06-30 Insys Therapeutics, Inc. Podjezično fentanilno pršilo
EP2007376B1 (en) * 2006-03-13 2013-05-08 Hadasit Medical Research Services And Development Ltd. Therapeutic uses of cannabidiol compounds
CN101951937A (zh) * 2007-12-21 2011-01-19 赫尔辛医疗股份公司 使用伊帕瑞林刺激胃肠系统动力的方法
US8846324B2 (en) * 2010-10-06 2014-09-30 Celltrend Gmbh In vitro method for diagnosing or predicting hypertension and/or early-stage cardiovascular end-organ damage by determining the concentration of soluble prorenin receptor
MX368865B (es) * 2013-09-17 2019-08-02 Vectus Biosystems Ltd Composiciones para el tratamiento de hipertension y/o fibrosis.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101522181A (zh) * 2006-10-04 2009-09-02 纽若科伊公司 诱导低体温药物在治疗局部缺血的应用
US20150080460A1 (en) * 2013-09-18 2015-03-19 Board Of Regents Of The University Of Nebraska Methods for Administration and Methods for Treating Cardiovascular Diseases with Resiniferatoxin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WANG, HANJUN; ZUCKER, IRVING H.: "Abstract P216: Thoracic Epidural Administration of Resiniferatoxin Improves Cardiac and Autonomic Dysfunction in Post-MI Rats", HYPERTENSION, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 66, no. Suppl 1, 3 November 2015 (2015-11-03), US , pages AP 216, XP009515877, ISSN: 0194-911X *

Also Published As

Publication number Publication date
IL298314B1 (en) 2024-12-01
JP6980694B2 (ja) 2021-12-15
JP7341203B2 (ja) 2023-09-08
CA3020815A1 (en) 2017-10-19
IL262328B (en) 2022-12-01
US20250082605A1 (en) 2025-03-13
EP3442523A1 (en) 2019-02-20
IL298314B2 (en) 2025-04-01
KR20190029511A (ko) 2019-03-20
KR102508022B1 (ko) 2023-03-10
IL298314A (en) 2023-01-01
KR102395342B1 (ko) 2022-05-10
IL262328A (en) 2018-11-29
AU2017248665A1 (en) 2018-11-08
JP2022001608A (ja) 2022-01-06
US20220000837A1 (en) 2022-01-06
CN109562096A (zh) 2019-04-02
EP3442523A4 (en) 2019-12-04
IL262328B2 (en) 2023-04-01
KR20220062667A (ko) 2022-05-17
JP2023155365A (ja) 2023-10-20
CN120114438A (zh) 2025-06-10
US20170296506A1 (en) 2017-10-19
WO2017180907A1 (en) 2017-10-19
JP2019511536A (ja) 2019-04-25

Similar Documents

Publication Publication Date Title
US20250082605A1 (en) Methods for Administration and Methods for Treating Cardiovascular Diseases with Resiniferatoxin
Tong et al. Liposomal bupivacaine and clinical outcomes
Choi et al. Combined low-dose spinal-epidural anesthesia versus single-shot spinal anesthesia for elective cesarean delivery
KR20220132666A (ko) 지속성 국소 마취용 네오삭시톡신 조합 제형
Geiger et al. Evaluation of the safety and efficacy of deep sedation for electrophysiology procedures administered in the absence of an anesthetist
Issa et al. Intrathecal clonidine reduces the incidence of ischemia-provoked ventricular arrhythmias in a canine postinfarction heart failure model
CA3020815C (en) Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
JP2620642B2 (ja) 麻薬性鎮痛剤とベンゾジアゼピンとを組み合わせて非経口投与した後に観察される平均血圧の低下を拮抗させるための医薬品
Royal Resiniferatoxin for permanent pain relief in cancer patients
RU2267335C1 (ru) Способ комбинированной анальгезии у пожилых пациентов после операций на тазобедренном суставе и бедре
Dasta Local anesthetics: evolving to a new standard of care
Johnson Treatment of acute pain in cats
Dikmen et al. The effects of adding tramadol to ropivacaine on axillary brachial plexus blockade in uremic patients
Borah et al. Midazolam as adjuvant: comparison between bupivacaine and ropivacaine in potentiation of anaesthetic effect in supraclavicular block.
Sudhakaran et al. A prospective study evaluating the effectiveness of epidural volume extension with normal saline in combined spinal epidural anesthesia for lower limb orthopedic surgeries using low dose intrathecal hyperbaric bupivacaine.
Chairmana et al. Best Practice & Research Clinical Anaesthesiology
Staudt et al. Neuromodulation for Non-urologic Chronic Pain
WO2022175973A1 (en) An injectable composition for long term delivery of nalbuphine or nalbuphine ester prodrug or its salts and use thereof
Khandagale et al. A REVIEW ON LOCAL ANESTHETIC SUSTAINED-RELEASE PAIN MANAGEMENT
Dhakal et al. A Comparative Clinical Evaluation of Efficacy of Midazolam as an Adjuvant to Bupivacaine in Brachial Plexus Block by Supraclavicular Approach for Upper Limb Surgery
US20170151207A1 (en) Ester and Cholinesterase Inhibitor in Long-Acting Nerve Block
Mahajan et al. THE ANALGESIC EFFICACY AND SAFETY OF EPIDURAL CLONIDINE FOR POST OPERATIVE ANALGESIA IN PATIENTS UNDERGOING LUMBOSACRAL SURGERY
Konstantatos Drugs used for anaesthesia and sedation
Shalaby Ahmed Adel Abd El Fattah El beleehy
EP1762239A1 (en) Lofexidine for intraspinal administration

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)